In 2018, the safety and efficacy of gefitinib as an adjuvant treatment was evaluated in a single-center retrospective study compared to standard two-drug adjuvant chemotherapy in patients with stage II-IIIA NSCLC with occurring activating mutations in the TK domain of the EGFR gene [49]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.